Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

• Status: Recruiting
• Trial end date: 2025-04-08
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 1, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and then in combination with endocrine therapy.

In Part 1A, single escalating doses of PF-07220060 alone will be administered to determine the maximum tolerated dose (MTD) and select the recommended phase 2 dose (RP2D).

In Part 1B and Part 1C, PF-07220060 will be administered in combination with 1 of 2 endocrine therapies (letrozole and fulvestrant, respectively).

In Part 1D, food effect assessment of PF-07220060 at the RP2D dose level from the Part 1A will be conducted.

Part 1B and Part 1C may commence at MTD or before reaching the MTD at a dose level in Part 1A.

Part 2B and Part 2C are expansion for combination therapy of PF-07220060 with letrozole and fulvestrant, respectively.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Fulvestrant; Letrozole

Criteria

Inclusion Criteria

• Part 1: Breast Cancer (BC)

• Refractory Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) BC

• Part 1A/Part 1D also include: Refractory HR-positive/HER2-positive BC

• Part 1: Tumors other than BC (Part 1A/Part 1D): NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification according to local standard tests

• Part 2:

• HR-positive/HER2-negative BC

• Patients who are either postmenopausal women or pre/peri-menopausal (Part 2C only)

• Lesion:

• Part 1: evaluable lesion (including skin or bone lesion only)

• Part 2: measurable lesion per RECIST v1.1

• Prior systemic Treatment

• Part 1: HR-positive/HER2-negative BC

• At least 1 line of SOC, including CD4/6 inhibitor therapy for advanced or metastatic disease, or if CDK4/6 inhibitors are not considered appropriate in the opinion of the investigator

• At least 1 line of anti-endocrine in countries without CDK4/6 inhibitor approval or reimbursement, for advanced or metastatic disease

• HR-positive/HER2-positive BC (Parts 1A/1D): at least 1 prior treatment of approved HER2 targeting therapy

• Tumors other than BC (Parts 1A/1D): tumor that is resistant to at least 2 lines of SOC for advanced or recurrent disease or for which no standard therapy is available

• Part 2B: participants who have not received any prior systemic anti-cancer therapies for advanced/metastatic BC

• Part 2C:

• Progressed during treatment or within 12 months of completion of adjuvant therapy with an aromatase inhibitor if postmenopausal, or tamoxifen if pre or perimenopausal, or

• Progressed while on or within 1 month after the endo the prior aromatase inhibitor therapy for advanced/metastatic BC if postmenopausal or prior endocrine treatment for advanced/metastatic BC if pre or perimenopausal

• One previous line of chemotherapy for advanced/metastatic disease is allowed in addition to endocrine therapy

General Inclusion Criteria

• All participants must be refractory to or intolerant of existing therapies known to provide clinical benefit for their condition.

• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1

• Adequate renal, liver, and bone marrow function

Exclusion Criteria:

• Part 1D: participants who have had a gastrectomy or have dietary or other restrictions that preclude a 10 hour overnight fast or consumption of the high fat, high calorie meal

• Part 2B: prior neoadjuvant or adjuvant treatment with a non-steroidal aromatase inhibitor with disease recurrence while on or within 12 months of completing treatment. Prior treatment with any CDK4/6 inhibitor

• Part 2C: prior treatment with any CDK inhibitor, fulvestrant, everolimus, or any agent whose mechanism of action is to inhibit the PI3K-mTOR pathway

• Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases carcinomatous meningitis, or leptomeningeal disease

• Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ

• Major surgery or radiation within 4 weeks prior to study intervention

• Last anti-cancer treatment within 2 weeks prior to study intervention

• Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry

• Pregnant or breastfeeding female participant

• Active inflammatory gastrointestinal (GI) disease, known diverticular disease or previous gastric resection or lap band surgery including impairment of gastrointestinal function or GI disease